AZD 6423

Drug Profile

AZD 6423

Alternative Names: AZD-6423

Latest Information Update: 14 Oct 2015

Price : $50

At a glance

  • Originator AstraZeneca
  • Class
  • Mechanism of Action NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Suicidal ideation

Most Recent Events

  • 24 Sep 2013 Phase-I clinical trials in Suicidal ideation (in volunteers) in USA (IV)
  • 19 Aug 2013 Preclinical trials in Suicidal ideation in United Kingdom (IV)
  • 19 Aug 2013 AstraZeneca plans a phase I trial in Healthy volunteers in USA (NCT01926366)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top